[go: up one dir, main page]

MX2013008851A - Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. - Google Patents

Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Info

Publication number
MX2013008851A
MX2013008851A MX2013008851A MX2013008851A MX2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A MX 2013008851 A MX2013008851 A MX 2013008851A
Authority
MX
Mexico
Prior art keywords
methods
chronic inflammation
compostions
inflammatory diseases
treating chronic
Prior art date
Application number
MX2013008851A
Other languages
English (en)
Other versions
MX346224B (es
Inventor
John Brew
Robin Mark Bannister
Gregory Alan Stoloff
Suzanne Jane Dilly
Wilson Caparros-Wanderley
Gemma Szucs
Olga Pleguezuelos Mateo
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46602107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013008851(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1101937.9A external-priority patent/GB201101937D0/en
Priority claimed from GBGB1113730.4A external-priority patent/GB201113730D0/en
Priority claimed from GBGB1113729.6A external-priority patent/GB201113729D0/en
Priority claimed from GB1113728.8A external-priority patent/GB2487808A/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of MX2013008851A publication Critical patent/MX2013008851A/es
Publication of MX346224B publication Critical patent/MX346224B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fertilizers (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente especificación describe composiciones farmacéuticas, métodos para preparar tales composiciones farmacéuticas, y métodos y usos para tratar una inflamación crónica y/o una enfermedad inflamatoria en un individuo que usa dichas composiciones farmacéuticas.
MX2013008851A 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. MX346224B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1101937.9A GB201101937D0 (en) 2011-02-04 2011-02-04 Method of preparing a composition
GBGB1113730.4A GB201113730D0 (en) 2011-08-10 2011-08-10 Solid dosage form
GBGB1113729.6A GB201113729D0 (en) 2011-08-10 2011-08-10 Hyperlipidaemia
GB1113728.8A GB2487808A (en) 2010-10-29 2011-08-10 Oral adjuvant or formulation comprising a lipid and an alcohol
PCT/GB2011/052115 WO2012056251A1 (en) 2010-10-29 2011-10-31 Inflammatory disease
PCT/GB2012/050242 WO2012104655A2 (en) 2011-02-04 2012-02-03 Compostions and methods for treating chronic inflammation and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013008851A true MX2013008851A (es) 2013-12-16
MX346224B MX346224B (es) 2017-03-10

Family

ID=46602107

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013008850A MX364229B (es) 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2013008851A MX346224B (es) 2011-02-04 2012-02-03 Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013008850A MX364229B (es) 2011-02-04 2012-02-03 Composiciones y metodos para tratar enfermedades cardiovasculares.

Country Status (12)

Country Link
EP (4) EP2670390A2 (es)
JP (3) JP2014504629A (es)
CN (2) CN103391768B (es)
AU (2) AU2012213218C1 (es)
BR (2) BR112013019734A2 (es)
CA (2) CA2826506C (es)
ES (1) ES2981782T3 (es)
MX (2) MX364229B (es)
RU (3) RU2635188C2 (es)
SG (3) SG192621A1 (es)
WO (2) WO2012104654A1 (es)
ZA (2) ZA201305783B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882356B (zh) * 2003-11-20 2015-02-25 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
BR112013019734A2 (pt) 2011-02-04 2016-10-25 Biocopea Ltd composições e métodos para tratar inflamação crônica e doenças inflamatórias
WO2013169797A1 (en) 2012-05-07 2013-11-14 Omthera Pharmaceuticals, Inc. Compositions of statins and omega-3 fatty acids
EP2911659A2 (en) * 2012-10-24 2015-09-02 Biocopea Limited Drug combinations and uses
AU2014204737B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Solid solution compositions and use in severe pain
HK1217650A1 (zh) * 2013-01-14 2017-01-20 Infirst Healthcare Limited 用於治疗剧痛的组合物及方法
AU2014204733B2 (en) 2013-01-14 2016-09-08 Clinics Operations Limited Cancer drug and uses
JP6474352B2 (ja) * 2013-02-04 2019-02-27 インファースト ヘルスケア リミテッド 慢性炎症及び炎症性疾患を治療する組成物と方法
KR101344218B1 (ko) * 2013-05-15 2013-12-20 충남대학교산학협력단 페노피브레이트를 함유하는 결핵 치료용 약학 조성물
RU2623876C2 (ru) * 2014-11-10 2017-06-29 Александр Владимирович Диковский Фармацевтическая композиция для лечения гиперлипидемии
KR101512606B1 (ko) 2014-12-11 2015-04-15 (주)이지코스 주름 및 아토피 개선과 피부 보습을 위한 화장료 조성물
CN105853405B (zh) * 2015-01-23 2019-03-08 中国科学院上海药物研究所 苯溴马隆在制备电压门控钾离子通道kcnq激动剂中的应用
EP3277280B1 (en) * 2015-03-31 2023-09-13 Mymd Pharmaceuticals, Inc. Isomyosmine for use in the treatment of autoimmune diseases
EP3095465A1 (en) 2015-05-19 2016-11-23 U3 Pharma GmbH Combination of fgfr4-inhibitor and bile acid sequestrant
JP2018522853A (ja) * 2015-06-15 2018-08-16 バイタル セラピーズ インコーポレーティッド 抗炎症反応を誘発するための組成物及び方法
CN105294672A (zh) * 2015-12-07 2016-02-03 范秀华 一种治疗子宫内膜炎的药物组合物
CN105753826A (zh) * 2016-05-09 2016-07-13 宋晓梅 一种吉非罗齐的药物组合物及其医药用途
CN106074500A (zh) * 2016-07-08 2016-11-09 重庆医药高等专科学校 脱氢洛伐他汀在制备抗炎症性肠病药物中的应用
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
US20180125795A1 (en) * 2017-01-03 2018-05-10 Thermolife International, Llc Cinnamaldehyde compositions and methods
JP6784973B2 (ja) * 2017-03-30 2020-11-18 国立研究開発法人産業技術総合研究所 単層カーボンナノチューブ
WO2018230751A1 (ko) * 2017-06-14 2018-12-20 주식회사 바이오솔루션 물질 p를 포함하는 주름 개선 또는 항염증 화장료 조성물
US11666542B2 (en) * 2017-07-18 2023-06-06 Deyi Pharmarmaceutical Ltd. Use of cannabidiol in treatment of pulmonary hypertension
EP3654953A4 (en) * 2017-07-19 2021-05-19 Ironwood Pharmaceuticals, Inc. EFFECTIVENESS OF A DOSAGE FORM OF GASTRIC-RETENTED BILIARY ACID SEQUESTRANT
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11452707B2 (en) * 2017-08-31 2022-09-27 Hanyi Bio-Technology (Beijing) Co., Ltd. Use of cannabidiol in preparation of drugs for resisting against influenza
CN109419786B (zh) * 2017-08-31 2021-04-30 汉义生物科技（北京）有限公司 大麻二酚在制备抗流感的药物中的用途
JP7290870B2 (ja) * 2018-01-12 2023-06-14 メティメディ ファーマシューティカルズ カンパニー リミテッド 慢性炎症性疾患を処置する方法
CN112512519B (zh) * 2018-06-03 2023-09-15 陈文彬 治疗致密化不全心肌症的方法
US20210393572A1 (en) * 2018-09-28 2021-12-23 Visceral Therapeutics Inc. Pharmaceutically active cannabis-based compositions and methods of use for treating gastrointestinal conditions
EP4272731A3 (en) 2018-12-11 2024-02-14 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
CN109846885A (zh) * 2019-04-04 2019-06-07 南通大学附属医院 瑞舒伐他汀的新用途
WO2021113912A1 (en) * 2019-12-11 2021-06-17 Ambetex Pty Ltd Therapeutic compositions and methods for prevention and treatment of diastolic dysfunction
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
TWI878456B (zh) 2020-02-18 2025-04-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
JP7764366B2 (ja) 2020-04-20 2025-11-05 株式会社 資生堂 光老化及び／又は真皮色素沈着を予防及び／又は改善する剤，それを用いた美容方法，及びその方法に適用するための美容装置
RU2745687C1 (ru) * 2020-05-19 2021-03-30 Всеволод Иванович Киселев Способ лечения эндометриоза с болевым синдромом и фармацевтическая композиция для его реализации
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
CN112156089A (zh) * 2020-09-27 2021-01-01 天津国际生物医药联合研究院 苯溴马隆在抗结核分枝杆菌感染中的应用
JP2024511208A (ja) 2021-03-27 2024-03-12 ティーアールエックス バイオサイエンシズ リミテッド 治療薬のバイオアベイラビリティを改善した組成物
KR20230050232A (ko) * 2021-10-07 2023-04-14 주식회사 이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
US20250360119A1 (en) * 2022-06-15 2025-11-27 The Johns Hopkins University Thiazolidinediones for the treatment of muscular dystrophies
EP4563012A4 (en) * 2022-12-08 2025-10-22 Beijing No 1 Bio Tech Development Co Ltd USE OF BOVINE SPLEEN PEPTIDE POWDER IN IMPROVING SLEEP, PREVENTING OR TREATING DEPRESSION, OR IMPROVING INTESTINAL FUNCTION
CN118903091B (zh) * 2024-06-21 2025-05-30 新乡医学院 神经酸在制备防治银屑病的药物中的应用
CN119033748B (zh) * 2024-08-21 2025-08-01 南方医科大学南方医院 环丙贝特在制备抗乙型肝炎病毒的药物中的应用
CN120037240B (zh) * 2025-04-17 2025-08-26 暨南大学 甘草次酸或甘草次酸脂质体在制备腹主动脉瘤保护药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
US5059626A (en) * 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
IT1255007B (it) * 1991-07-01 1995-10-11 Altergon Sa Sale solubile dell'ibuprofen c0n n-(2-idrossietil) pirrolidina e composizioni farmaceutiche che li contengono.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2365128A1 (en) * 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MXPA03005550A (es) * 2000-12-19 2004-05-14 Univ Texas Formulaciones de nsaid que comprenden aceites de lecitina para proteger el tracto gastrointestinal y proporcionar actividad terapeutica mejorada.
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
JP2005068060A (ja) * 2003-08-22 2005-03-17 Nrl Pharma Inc ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法
CN100486567C (zh) * 2004-08-12 2009-05-13 山东绿叶天然药物研究开发有限公司 姜黄素乳剂及其制备方法
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
WO2008070950A1 (en) * 2006-12-13 2008-06-19 Laboratoires Mauves Inc. Pharmaceutical solution formulations for encapsulation into gelatin capsules or other dosage forms
WO2008144355A2 (en) * 2007-05-17 2008-11-27 Morton Grove Pharmaceuticals, Inc. Stable, self-microemulsifying fenofibrate compositions
WO2009033131A2 (en) * 2007-09-07 2009-03-12 Novavax, Inc. Multi-phasic, nano-structured compositions containing a combination of a fibrate and a statin
RU2363451C2 (ru) * 2007-09-14 2009-08-10 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция для приготовления обладающей пролонгированным действием лекарственной формы и способ получения этой формы
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
GB2477590A (en) 2010-02-05 2011-08-10 Biocopea Ltd A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
GB201018289D0 (en) 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
BR112013019734A2 (pt) 2011-02-04 2016-10-25 Biocopea Ltd composições e métodos para tratar inflamação crônica e doenças inflamatórias

Also Published As

Publication number Publication date
CA2826452A1 (en) 2012-08-09
AU2012213217B2 (en) 2017-04-20
AU2012213218B2 (en) 2017-01-12
WO2012104655A3 (en) 2013-03-14
ZA201305783B (en) 2014-04-30
SG192620A1 (en) 2013-09-30
WO2012104654A1 (en) 2012-08-09
ES2981782T3 (es) 2024-10-10
CN103391768A (zh) 2013-11-13
EP2670389A1 (en) 2013-12-11
NZ711187A (en) 2016-01-29
EP4397373A2 (en) 2024-07-10
EP3494961A1 (en) 2019-06-12
MX2013008850A (es) 2016-09-23
SG10201600854SA (en) 2016-03-30
MX346224B (es) 2017-03-10
CA2826452C (en) 2016-11-22
NZ613812A (en) 2015-08-28
CN103391767B (zh) 2016-08-31
EP2670390A2 (en) 2013-12-11
CA2826506A1 (en) 2012-08-09
AU2012213217A1 (en) 2013-08-15
EP3494961C0 (en) 2024-04-10
NZ613805A (en) 2016-01-29
MX364229B (es) 2019-04-17
RU2013140776A (ru) 2015-03-10
CN103391768B (zh) 2016-08-10
BR112013019732B1 (pt) 2023-01-24
BR112013019734A2 (pt) 2016-10-25
AU2012213218C1 (en) 2017-04-20
EP3494961B1 (en) 2024-04-10
JP6273304B2 (ja) 2018-01-31
AU2012213218B9 (en) 2017-02-02
BR112013019732A2 (pt) 2016-10-25
AU2012213218A1 (en) 2013-08-15
SG192621A1 (en) 2013-09-30
EP4397373A3 (en) 2024-09-04
WO2012104655A2 (en) 2012-08-09
JP2014507429A (ja) 2014-03-27
ZA201305784B (en) 2014-04-30
RU2016138830A (ru) 2018-12-12
CN103391767A (zh) 2013-11-13
JP2016128482A (ja) 2016-07-14
RU2635188C2 (ru) 2017-11-09
RU2013140775A (ru) 2015-03-10
CA2826506C (en) 2017-07-25
JP2014504629A (ja) 2014-02-24

Similar Documents

Publication Publication Date Title
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
GB201209613D0 (en) New compounds
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX339243B (es) Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery
MX348147B (es) Biarilsulfonamidas utiles en el tratamiento de la inflamacion y cancer.
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
EP2672985A1 (en) Citrate free pharmaceutical compositions comprising anakinra
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
PH12020500472A1 (en) Autotaxin inhibitor compounds

Legal Events

Date Code Title Description
FG Grant or registration